NICE to appraise Bracco's contrast-enhanced ultrasound tech
This article was originally published in Clinica
The UK’s National Institute for Health and Clinical Excellence (NICE) is to appraise the contrast-enhanced ultrasound imaging agent SonoVue under its diagnostics health technology assessment (HTA) pathway. Manufacturers of rival products should note that the appraisal will also cover “other alternative technologies identified during scoping”. The schedule for the appraisal has not been announced yet. SonoVue – sulphur hexafluoride microbubbles – was developed by Bracco Diagnostics (Milan, Italy) and was launched in the EU in 2001.
You may also be interested in...
Senate Finance Committee’s approach to penalize companies for raising WAC list prices is not a ‘price control,’ but a reasonable approach to change the incentives that distort pricing in the supply chain, US HHS Secretary Alex Azar says.
With the pre-GDUFA backlog largely acted upon, the FDA expects ANDA approvals to decrease, but supplement actions to increase in FY 2020 and FY 2021.
February and March inspections deferred unless any are deemed mission critical. China director remains behind as staff evacuate.